BioMarin Pharmaceutical Announces Phase 3 VOXZOGO Study Data Demonstrating Statistically Significant Change From Baseline In Children With Hypochondroplasia

Benzinga Newsdesk www.benzinga.com Positive 91.2%

Neg 0% Neu 0% Pos 91.2%

Comments

No comments yet. Be the first!